ClinicalTrials.Veeva

Menu
R

Richmond Pharmacology | London, United Kingdom

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

FOR-6219
Moxifloxacin
Eplontersen
RV521
UPB-101
INZ-701
Cuprior®
AST-008
ION-682884
Trientine Base

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 43 total trials

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

The goal of this clinical trial is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participan...

Enrolling
Glanzmann Thrombasthenia
Drug: HMB-001

The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.

Enrolling
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Drug: Eplontersen

To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC). For more informa...

Active, not recruiting
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Drug: Eplontersen
Drug: Placebo

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics PD) of multiple ascending doses of INZ-7...

Active, not recruiting
ATP-Binding Cassette Subfamily C Member 6 Deficiency
Generalized Arterial Calcification of Infancy
Drug: INZ-701

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of INZ-...

Active, not recruiting
Autosomal Recessive Hypophosphatemic Rickets
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Drug: INZ-701

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

Enrolling
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Drug: Placebo
Biological: NTLA-2001

This trial will be a randomised, double-blind, sequential-group, multiple-dose, placebo-controlled, dose escalation trial to characterise the pharmac...

Enrolling
Pharmacokinetics
Drug: Noribogaine

Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Compl...

Active, not recruiting
Amyloid Cardiomyopathy, Transthyretin-Related
Drug: Acoramidis (AG10)

Trial sponsors

Alnylam Pharmaceuticals logo
Bristol-Myers Squibb (BMS) logo
Ionis Pharmaceuticals logo
Pfizer logo
A
Chiesi logo
E
F
H
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems